Literature DB >> 30535828

Recent advances in the identification and management of inherited hyperoxalurias.

David J Sas1, Peter C Harris2, Dawn S Milliner2.   

Abstract

Primary hyperoxaluria (PH) is caused by genetic mutations resulting in oxalate overproduction leading to nephrolithiasis, nephrocalcinosis, extrarenal manifestations, chronic kidney disease, and end-stage renal disease. Advances in genetic testing techniques have improved our ability to efficiently and effectively obtain a definitive diagnosis of PH as well as easily screen at-risk family members. Similarly, advances in technologies related to intervening at the genetic and molecular level promise to change the way we treat patients with PH. In this review, we provide an update regarding the identification of underlying molecular and biochemical causes of inherited hyperoxalurias, clinical manifestations, and treatment strategies.

Entities:  

Keywords:  Genetic; Kidney stones; Nephrolithiasis; Primary hyperoxaluria

Mesh:

Substances:

Year:  2018        PMID: 30535828     DOI: 10.1007/s00240-018-1093-3

Source DB:  PubMed          Journal:  Urolithiasis        ISSN: 2194-7228            Impact factor:   3.436


  70 in total

1.  Primary hyperoxaluria Type 1: indications for screening and guidance for diagnosis and treatment.

Authors:  Pierre Cochat; Sally-Anne Hulton; Cécile Acquaviva; Christopher J Danpure; Michel Daudon; Mario De Marchi; Sonia Fargue; Jaap Groothoff; Jérôme Harambat; Bernd Hoppe; Neville V Jamieson; Markus J Kemper; Giorgia Mandrile; Martino Marangella; Stefano Picca; Gill Rumsby; Eduardo Salido; Michael Straub; Christiaan S van Woerden
Journal:  Nephrol Dial Transplant       Date:  2012-05       Impact factor: 5.992

2.  An Investigational RNAi Therapeutic Targeting Glycolate Oxidase Reduces Oxalate Production in Models of Primary Hyperoxaluria.

Authors:  Abigail Liebow; Xingsheng Li; Timothy Racie; Julia Hettinger; Brian R Bettencourt; Nader Najafian; Patrick Haslett; Kevin Fitzgerald; Ross P Holmes; David Erbe; William Querbes; John Knight
Journal:  J Am Soc Nephrol       Date:  2016-07-18       Impact factor: 10.121

3.  Intra-familial clinical heterogeneity: absence of genotype-phenotype correlation in primary hyperoxaluria type 1 in Israel.

Authors:  Yaacov Frishberg; Choni Rinat; Adel Shalata; Ihab Khatib; Sofia Feinstein; Rachel Becker-Cohen; Irit Weismann; Ronald J A Wanders; Gill Rumsby; Frank Roels; Hanna Mandel
Journal:  Am J Nephrol       Date:  2005-06-15       Impact factor: 3.754

4.  Metabolism of (13)C5-hydroxyproline in mouse models of Primary Hyperoxaluria and its inhibition by RNAi therapeutics targeting liver glycolate oxidase and hydroxyproline dehydrogenase.

Authors:  Xingsheng Li; John Knight; Sonia Fargue; Brianna Buchalski; Zhengrong Guan; Edward W Inscho; Abigail Liebow; Kevin Fitzgerald; William Querbes; W Todd Lowther; Ross P Holmes
Journal:  Biochim Biophys Acta       Date:  2015-12-02

Review 5.  Primary hyperoxaluria type 1: still challenging!

Authors:  Pierre Cochat; Aurélia Liutkus; Sonia Fargue; Odile Basmaison; Bruno Ranchin; Marie-Odile Rolland
Journal:  Pediatr Nephrol       Date:  2006-06-30       Impact factor: 3.714

6.  Chronic renal failure in Iranian children.

Authors:  K Madani; H Otoukesh; A Rastegar; S Van Why
Journal:  Pediatr Nephrol       Date:  2001-02       Impact factor: 3.714

7.  The gene encoding hydroxypyruvate reductase (GRHPR) is mutated in patients with primary hyperoxaluria type II.

Authors:  S D Cramer; P M Ferree; K Lin; D S Milliner; R P Holmes
Journal:  Hum Mol Genet       Date:  1999-10       Impact factor: 6.150

8.  Mutations in DHDPSL are responsible for primary hyperoxaluria type III.

Authors:  Ruth Belostotsky; Eric Seboun; Gregory H Idelson; Dawn S Milliner; Rachel Becker-Cohen; Choni Rinat; Carla G Monico; Sofia Feinstein; Efrat Ben-Shalom; Daniella Magen; Irith Weissman; Celine Charon; Yaacov Frishberg
Journal:  Am J Hum Genet       Date:  2010-09-10       Impact factor: 11.025

9.  The Chaperoning Activity of Amino-oxyacetic Acid on Folding-Defective Variants of Human Alanine:Glyoxylate Aminotransferase Causing Primary Hyperoxaluria Type I.

Authors:  Elisa Oppici; Riccardo Montioli; Mirco Dindo; Laura Maccari; Valentina Porcari; Antonio Lorenzetto; Sara Chellini; Carla Borri Voltattorni; Barbara Cellini
Journal:  ACS Chem Biol       Date:  2015-07-27       Impact factor: 5.100

10.  A randomised Phase II/III study to evaluate the efficacy and safety of orally administered Oxalobacter formigenes to treat primary hyperoxaluria.

Authors:  Dawn Milliner; Bernd Hoppe; Jaap Groothoff
Journal:  Urolithiasis       Date:  2017-07-17       Impact factor: 3.436

View more
  12 in total

1.  Characteristics of the genotype and phenotype in Chinese primary hyperoxaluria type 1 populations.

Authors:  Fangzhou Zhao; Jun Li; Lei Tang; Chunming Li; Wenying Wang; Chen Ning
Journal:  Urolithiasis       Date:  2020-06-18       Impact factor: 3.436

2.  Empirical therapy or precision medicine for kidney stone formers in the '-omics' era?

Authors:  Giovanni Gambaro
Journal:  Urolithiasis       Date:  2018-11-29       Impact factor: 3.436

Review 3.  Novel therapeutic approaches for the primary hyperoxalurias.

Authors:  Ruth Belostotsky; Yaacov Frishberg
Journal:  Pediatr Nephrol       Date:  2020-11-06       Impact factor: 3.714

4.  Hydroxycitrate prevents calcium oxalate crystallization and kidney injury in a nephrolithiasis rat model.

Authors:  Bowei Yang; Jiongming Li; Bin Wang; Guang Wang; Pei Li; Haixiang Guo; Yuhang Li; Tongxin Yang
Journal:  Urolithiasis       Date:  2021-08-19       Impact factor: 3.436

Review 5.  Nephrocalcinosis: A Review of Monogenic Causes and Insights They Provide into This Heterogeneous Condition.

Authors:  Fay J Dickson; John A Sayer
Journal:  Int J Mol Sci       Date:  2020-01-06       Impact factor: 5.923

6.  Natural History of Clinical, Laboratory, and Echocardiographic Parameters of a Primary Hyperoxaluria Cohort on Long Term Hemodialysis.

Authors:  David J Sas; Felicity T Enders; Tina M Gunderson; Ramila A Mehta; Julie B Olson; Barbara M Seide; Carly J Banks; Bastian Dehmel; Patricia A Pellikka; John C Lieske; Dawn S Milliner
Journal:  Front Med (Lausanne)       Date:  2021-04-09

7.  Comprehensive Genetic Analysis Reveals Complexity of Monogenic Urinary Stone Disease.

Authors:  Andrea G Cogal; Jennifer Arroyo; Ronak Jagdeep Shah; Kalina J Reese; Brenna N Walton; Laura M Reynolds; Gabrielle N Kennedy; Barbara M Seide; Sarah R Senum; Michelle Baum; Stephen B Erickson; Sujatha Jagadeesh; Neveen A Soliman; David S Goldfarb; Lada Beara-Lasic; Vidar O Edvardsson; Runolfur Palsson; Dawn S Milliner; David J Sas; John C Lieske; Peter C Harris
Journal:  Kidney Int Rep       Date:  2021-09-08

Review 8.  The Crystalline Nephropathies.

Authors:  Mark A Perazella; Leal C Herlitz
Journal:  Kidney Int Rep       Date:  2021-09-17

9.  Clinical features of genetically confirmed patients with primary hyperoxaluria identified by clinical indication versus familial screening.

Authors:  David J Sas; Felicity T Enders; Ramila A Mehta; Xiaojing Tang; Fang Zhao; Barbara M Seide; Dawn S Milliner; John C Lieske
Journal:  Kidney Int       Date:  2019-12-13       Impact factor: 18.998

Review 10.  Catabolism of Hydroxyproline in Vertebrates: Physiology, Evolution, Genetic Diseases and New siRNA Approach for Treatment.

Authors:  Ruth Belostotsky; Yaacov Frishberg
Journal:  Int J Mol Sci       Date:  2022-01-17       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.